001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
22 févr. 2022 09h00 HE | Delcath Systems, Inc.
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at Upcoming Virtual Investor Conferences
10 févr. 2022 16h30 HE | Delcath Systems, Inc.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
07 févr. 2022 16h01 HE | Delcath Systems, Inc.
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
03 févr. 2022 16h30 HE | Delcath Systems, Inc.
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of...
001_Delcath_CorporateLogo_Tagline.png
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
25 janv. 2022 16h01 HE | Delcath Systems, Inc.
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
07 janv. 2022 09h00 HE | Delcath Systems, Inc.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
02 déc. 2021 08h00 HE | Delcath Systems, Inc.
On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
30 nov. 2021 08h30 HE | Delcath Systems, Inc.
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems Announces Third Quarter 2021 Results
09 nov. 2021 07h30 HE | Delcath Systems, Inc.
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
001_Delcath_CorporateLogo_Tagline.png
Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021
08 nov. 2021 09h00 HE | Delcath Systems, Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...